Immuunijärjestelmä ihosyövissä
Tutkimusryhmä
01.01.2022 -
Kliinisen lääketieteen yksikkö, Lääketieteen laitos, Terveystieteiden tiedekunta
Johtajat
Vanhemmat tutkijat
Julkaisut
10 kappaletta-
Mast Cells Are a Marked Source for Complement C3 Products That Associate with Increased CD11b-Positive Cells in Keratinocyte Skin Carcinomas
Rahkola, Dina; Laitala, Joel; Siiskonen, Hanna; Pelkonen, Jukka; Harvima, Ilkka T. 2019. Cancer investigation. 37: 73-84 -
Mast cell chymase degrades fibrinogen and fibrin
Lipitsä, T; Siiskonen, H; Naukkarinen, A; Harvima, IT. 2019. British journal of dermatology. 181: 296-303 -
Mast cell-neural interactions contribute to pain and itch
Gupta, Kalpna; Harvima, Ilkka T. 2018. Immunological reviews. 282: 168-187 -
CD40 Ligand Is Increased in Mast Cells in Psoriasis and Actinic Keratosis but Less So in Epithelial Skin Carcinomas
Haimakainen S, Kaukinen AP, Suttle M-M, Pelkonen J, Harvima IT. 2017. Cancer investigation. 35: 143-151 -
Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma
Siiskonen Hanna, Poukka Mari, Bykachev Andrey, Tyynelä-Korhonen Kristiina, Sironen Reijo, Pasonen-Seppänen Sanna, Harvima Ilkka T. 2015. Melanoma research. [epub ahead of print 27 July 2015]: - -
Molecular targets on mast cells and basophils for novel therapies
Harvima Ilkka T, Levi-Schaffer Francesca, Draber Petr, Friedman Sheli, Polakovicova Iva, Gibbs Bernhard F, Blank Ulrich, Nilsson Gunnar, Maurer Marcus. 2014. Journal of allergy and clinical immunology. 134: 530-544 -
Anti-apoptotic bfl-1 is the major effector in activation-induced human mast cell survival
Ekoff M, Lyberg K, Krajewska M, Arvidsson M, Rak S, Reed JC, Harvima I, Nilsson G. 2012. PLoS ONE. 7: e39117; 1-7 -
The BH3-Mimetic ABT-737 Induces Mast Cell Apoptosis In Vitro and In Vivo: Potential for Therapeutics
Mats Karlberg, Maria Ekoff, David C.S. Huang, Paula Mustonen, Ilkka T. Harvima & Gunnar Nilsson. 2010. Journal of immunology. 185: 2555-2562 -
Cervical squamous carcinoma cells are resistant to the combined action of tumor necrosis factor-alpha and histamine whereas normal keratinocytes undergo cytolysis
Diaconu N-C, Rummukainen J, Mättö M, Naukkarinen A, Harvima RJ, Pelkonen J, Harvima IT. 2008. Bmc cancer. 8: [15, art. 46] -
Mast cell CD30 ligand is upregulated in cutaneus inflammation and mediates degranulation-independent chemokine secretion
Fischer M, Harvima IT, Carvalho RFS, Möller C, Naukkarinen A, Enblad G, Nilsson G. 2006. Journal of clinical investigation. 116: 2748-2756